LENVIMA 10 mg hard capsules
Sponsors
Bluepharma Industria Farmaceutica S.A., Institut Gustave Roussy, Eisai Limited, Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, AstraZeneca AB
Conditions
Advanced Renal Cell CarcinomaAdvanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and are not candidates for curative surgery or radiation.Advanced or unresectable hepatocellular carcinoma in adults who have received no prior systemic therapy.Advanced solid tumorCentral Nervous System TumorsHepatocellular carcinomaLocally advanced head and neck squamous cell carcinomaMetastatic renal cell carcinoma (mRCC)
Phase 1
Comparative Bioavailability of Lenvatinib 10 mg Capsules: A Two-Part, Single-Dose, Open-Label, Randomized, Six-Sequence, Three-Treatment, Three-Period, Crossover Pilot Study in Healthy Subjects Under Fasting and Fed Conditions.
CompletedCTIS2022-501327-25-00
Start: 2023-05-13End: 2023-07-10Target: 36Updated: 2023-07-10
A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) in Subjects With Selected Tumor Types
Active, not recruitingCTIS2023-506868-14-00
Start: 2023-02-28Target: 90Updated: 2025-12-29
An Open-Label Study of E7386 in Combination With Other Anticancer Drug(s) in Subjects With Solid Tumors
Active, not recruitingCTIS2023-510275-64-00
Start: 2023-05-31Target: 83Updated: 2025-11-07
An open-label, multicenter, phase 1b/2 study of E7386 in combination with pembrolizumab in previously treated subjects with selected solid tumors
CompletedCTIS2023-505425-14-00
Start: 2022-08-11End: 2024-10-15Target: 30Updated: 2024-09-30
A Phase 1b, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in Combination with Axitinib in Subjects with Advanced Renal Cell Carcinoma
Active, not recruitingCTIS2023-509604-15-00
Start: 2021-02-15Target: 93Updated: 2025-11-20
Single-arm, multicenter Phase I/Ib study of avelumab + lenvatinib in children with primary CNS tumors
SuspendedCTIS2024-512940-51-00
Start: 2021-11-24Target: 23Updated: 2025-10-16
Phase 2
A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile: The Drug Rediscovery Protocol (DRUP trial)
RecruitingCTIS2023-509152-33-00
Start: 2016-07-25Target: 3000Updated: 2025-12-19
LENVAGIST - A multicentre, comparative, placebo-controlled, double-blinded, phase II study of the efficacy of lenvatinib in patients with locally advanced or metastatic GIST after failure of imatinib and sunitinib
CompletedCTIS2024-513984-22-00
Start: 2020-03-17End: 2025-03-12Target: 74Updated: 2025-11-19
Combined Pembrolizumab and Lenvatinib after definitive Chemoradiation of locally advanced HNSCC
in PD-L1 positive patients (CPS≥1)
Active, not recruitingCTIS2024-516536-10-00
Start: 2023-05-25Target: 50Updated: 2025-10-06
PEMbrolizumab Plus Lenvatinib In Second Line And Third Line Malignant Pleural MEsotheLiomA Patients: A Single Arm Phase II Study (PEMMELA).
Active, not recruitingCTIS2024-516618-39-00
Start: 2021-02-25Target: 58Updated: 2024-09-24
rEECur: International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma
RecruitingCTIS2024-516078-31-00
Start: 2015-05-05Target: 436Updated: 2024-12-04